S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in

Curis Stock Forecast, Price & News

-0.69 (-6.30 %)
(As of 01/25/2021 12:00 AM ET)
Today's Range
Now: $10.27
50-Day Range
MA: $9.04
52-Week Range
Now: $10.27
Volume2.09 million shs
Average Volume2.46 million shs
Market Capitalization$604.05 million
P/E RatioN/A
Dividend YieldN/A
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation; and Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors. The company's products in pipeline include CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and DarwinHealth, Inc. to characterize biomarkers and tumor subtype alignments to identify therapeutic opportunities. The company was founded in 2000 and is headquartered in Lexington, Massachusetts.
Curis logo


Overall MarketRank

1.15 out of 5 stars

Medical Sector

876th out of 1,922 stocks

Biological Products, Except Diagnostic Industry

113th out of 177 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CRIS
Year FoundedN/A



Sales & Book Value

Annual Sales$10 million
Book Value($1.02) per share


Net Income$-32,140,000.00
Net Margins-279.33%


Market Cap$604.05 million
Next Earnings Date3/18/2021 (Estimated)
-0.69 (-6.30 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for CRIS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Curis (NASDAQ:CRIS) Frequently Asked Questions

How has Curis' stock price been impacted by COVID-19 (Coronavirus)?

Curis' stock was trading at $1.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRIS stock has increased by 842.2% and is now trading at $10.27.
View which stocks have been most impacted by COVID-19

Is Curis a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Curis stock.
View analyst ratings for Curis
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Curis?

Wall Street analysts have given Curis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Curis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Curis' next earnings date?

Curis is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Curis

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings data on Sunday, November, 15th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $2.74 million for the quarter. During the same period in the previous year, the company earned ($0.26) EPS.
View Curis' earnings history

When did Curis' stock split? How did Curis' stock split work?

Curis shares reverse split on the morning of Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRIS?

3 analysts have issued twelve-month price targets for Curis' stock. Their forecasts range from $5.00 to $16.00. On average, they anticipate Curis' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts' price targets for Curis
or view Wall Street analyst' top-rated stocks.

Are investors shorting Curis?

Curis saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,970,000 shares, an increase of 951.1% from the December 15th total of 377,700 shares. Based on an average daily trading volume, of 8,340,000 shares, the short-interest ratio is currently 0.5 days.
View Curis' Short Interest

Who are some of Curis' key competitors?

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Who are Curis' key executives?

Curis' management team includes the following people:
  • Mr. James E. Dentzer, Pres, CEO & Director (Age 54, Pay $708.26k)
  • Mr. William E. Steinkrauss, Chief Financial Officer (Age 35, Pay $441.29k)
  • Dr. Robert E. Martell, Head of R&D (Age 58, Pay $481.87k)
  • Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 62)
  • Dr. Reinhard Wilhelm von Roemeling, Sr. VP of Clinical Devel.

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Sterling Investment Advisors Ltd. (0.01%).
View institutional ownership trends for Curis

Which major investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including Sterling Investment Advisors Ltd..
View insider buying and selling activity for Curis
or view top insider-selling stocks.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $10.27.

How big of a company is Curis?

Curis has a market capitalization of $604.05 million and generates $10 million in revenue each year. The biotechnology company earns $-32,140,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Curis employs 28 workers across the globe.

What is Curis' official website?

The official website for Curis is www.curis.com.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]

This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.